Targeted therapy of brain ischaemia using Fas ligand antibody conjugated PEG-lipid nanoparticles

Biomaterials

Volumn 35, Issue 1, 2014, Pages 530-537

  Lu, Ying mei ^a   Huang, Ji yun ^b   Wang, Huan ^b   Lou, Xue fang ^a   Liao, Mei hua ^b   Hong, Ling juan ^b   Tao, Rong rong ^b   Ahmed, Muhammad M ^b   Shan, Chun lei ^c   Wang, Xiao liang ^d   Fukunaga, Kohji ^e   Du, Yong zhong ^c   Han, Feng ^b  

^a ZHEJIANG UNIVERSITY CITY COLLEGE   (China)

^b ZHEJIANG UNIVERSITY   (China)

^c ZHEJIANG UNIVERSITY   (China)

^d INSTITUTE OF MATERIA MEDICA   (China)

^e TOHOKU UNIVERSITY   (Japan)

Author keywords

3 n Butylphthalide; Brain ischaemia; Brain targeted delivery; Fas ligand; PEGylated lipid nanoparticles

Indexed keywords

3-N-BUTYLPHTHALIDE; BRAIN-TARGETED DELIVERY; FAS LIGAND; ISCHAEMIA; PEGYLATED LIPIDS;

DRUG DELIVERY; LIGANDS; MAMMALS; NANOPARTICLES;

ANTIBODIES;

3 BUTYLPHTHALIDE; FAS ANTIBODY; FAS LIGAND ANTIBODY; NANOCARRIER; PEGYLATED LIPID NANOPARTICLE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN INJURY; BRAIN ISCHEMIA; CONTROLLED STUDY; DRUG EFFICACY; FLUORESCENCE ANALYSIS; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; MALE; MICROGLIA; MOUSE; NEUROLOGIC DISEASE; NONHUMAN; PRIORITY JOURNAL;

MUS;

3-N-BUTYLPHTHALIDE; BRAIN ISCHAEMIA; BRAIN-TARGETED DELIVERY; FAS LIGAND; PEGYLATED LIPID NANOPARTICLES;

ANIMALS; ANTIBODIES; BRAIN ISCHEMIA; DISEASE MODELS, ANIMAL; FAS LIGAND PROTEIN; LIPIDS; MICE; NANOPARTICLES; POLYETHYLENE GLYCOLS;

EID: 84887014984     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2013.09.093     Document Type: Article

References (36)

1. Lo E.H., Dalkara T., Moskowitz M.A. Mechanisms, challenges and opportunities in stroke. Nat Rev Neurosci 2003, 4:399-415.
2. Patel R.D., Saver J.L. Evolution of reperfusion therapies for acute brain and acute myocardial ischemia; a systematic, comparative analysis. Stroke 2013, 44:94-98.
3. Tao R.R., Ji Y.L., Lu Y.M., Fukunaga K., Han F. Targeting nitrosative stress for neurovascular protection: new implications in brain diseases. Curr Drug Targets 2012, 13:272-284.
4. Kilic U., Yilmaz B., Ugur M., Yüksel A., Reiter R.J., Hermann D.M., et al. Evidence that membrane-bound G protein-coupled melatonin receptors MT1 and MT2 are not involved in the neuroprotective effects of melatonin in focal cerebral ischemia. JPineal Res 2012, 52:228-235.
5. Neuwelt E., Abbott N.J., Abrey L., Banks W.A., Blakley B., Davis T., et al. Strategies to advance translational research into brain barriers. Lancet Neurol 2008, 7:84-96.
6. Pardridge W.M. The blood-brain barrier: bottleneck in brain drug development. NeuroRx 2005, 2:3-14.
7. Orive G., Anitua E., Pedraz J.L., Emerich D.F. Biomaterials for promoting brain protection, repair and regeneration. Nat Rev Neurosci 2009, 10:682-692.
8. Liu L., Guo K., Lu J., Venkatraman S.S., Luo D., Ng K.C., et al. Biologically active core/shell nanoparticles self-assembled from cholesterol-terminated PEG-TAT for drug delivery across the blood-brain barrier. Biomaterials 2008, 29:1509-1517.
9. Weiss P.S. Nanotechnology: a molecular four-wheel drive. Nature 2011, 479:187-188.
10. Andrews A.M., Weiss P.S. Nano in the brain: nano-neuroscience. ACS Nano 2012, 6:8463-8464.
11. Weiss P.S. Nanoscience and nanotechnology: present and future. ACS Nano 2010, 4:1771-1772.
12. Lanza G.M., Marsh J.N., Hu G., Scott M.J., Schmieder A.H., Caruthers S.D., et al. Rationale for a nanomedicine approach to thrombolytic therapy. Stroke 2010, 41:S42-S44.
13. Higgins P., Dawson J., Walters M. Nanomedicine: nanotubes reduce stroke damage. Nat Nanotechnol 2011, 6:83-84.
14. Kaur I.P., Bhandari R., Bhandari S., Kakkar V. Potential of solid lipid nanoparticles in brain targeting. JControl Release 2008, 127:97-109.
15. Lu Y.M., Tao R.R., Huang J.Y., Li L.T., Liao M.H., Li X.M., et al. P2X7 signalling promotes microsphere embolism-triggered microglia activation by maintaining elevation of fas ligand. JNeuroinflammation 2012, 9:172.
16. Wang Y., Wang B., Zhu M.T., Li M., Wang H.J., Wang M., et al. Microglial activation, recruitment and phagocytosis as linked phenomena in ferric oxide nanoparticle exposure. Toxicol Lett 2011, 205:26-37.
17. Yuan H., Chen J., Du Y.Z., Hu F.Q., Zeng S., Zhao H.L. Studies on oral absorption of stearic acid SLN by a novel fluorometric method. Colloids Surf B Biointerfaces 2007, 58:157-164.
18. Shioda N., Han F., Moriguchi S., Fukunaga K. Constitutively active calcineurin mediates delayed neuronal death through fas-ligand expression via activation of NFAT and FKHR transcriptional activities in mouse brain ischemia. JNeurochem 2007, 102:1506-1517.
19. Han F., Chen Y.X., Lu Y.M., Huang J.Y., Zhang G.S., Tao R.R., et al. Regulation of the ischemia-induced autophagy-lysosome processes by nitrosative stress in endothelial cells. JPineal Res 2011, 51:124-135.
20. Gao Y., Gu W., Chen L., Xu Z., Li Y. The role of daidzein-loaded sterically stabilized solid lipid nanoparticles in therapy for cardio-cerebrovascular diseases. Biomaterials 2008, 29:4129-4136.
21. Liu X., An C., Jin P., Liu X., Wang L. Protective effects of cationic bovine serum albumin-conjugated PEGylated tanshinone IIA nanoparticles on cerebral ischemia. Biomaterials 2013, 34:817-830.
22. Zhang Y., Wang L., Li J., Wang X.L. 2-(1-Hydroxypentyl)-benzoate increases cerebral blood flow and reduces infarct volume in rats model of transient focal cerebral ischemia. JPharmacol Exp Ther 2006, 317:973-979.
23. Zhang G.S., Tian Y., Huang J.Y., Tao R.R., Liao M.H., Lu Y.M., et al. The γ-Secretase blocker DAPT reduces the permeability of the blood-brain barrier by decreasing the ubiquitination and degradation of occludin during permanent brain ischemia. CNS Neurosci Ther 2013, 19:53-60.
24. Tai S.H., Chen H.Y., Lee E.J., Chen T.Y., Lin H.W., Hung Y.C., et al. Melatonin inhibits postischemic matrix metalloproteinase-9 (MMP-9) activation via dual modulation of plasminogen/plasmin system and endogenous MMP inhibitor in mice subjected to transient focal cerebral ischemia. JPineal Res 2010, 49:332-341.
25. Silva G.A. Neuroscience nanotechnology: progress, opportunities and challenges. Nat Rev Neurosci 2006, 7:65-74.
26. Ren J., Shen S., Wang D., Xi Z., Guo L., Pang Z., et al. The targeted delivery of anticancer drugs to brain glioma by PEGylated oxidized multi-walled carbon nanotubes modified with angiopep-2. Biomaterials 2012, 33:3324-3333.
27. Kim J.Y., Choi W.I., Kim Y.H., Tae G. Brain-targeted delivery of protein using chitosan- and RVG peptide-conjugated, pluronic-based nano-carrier. Biomaterials 2013, 34:1170-1178.
28. Li J., Feng L., Fan L., Zha Y., Guo L., Zhang Q., et al. Targeting the brain with PEG-PLGA nanoparticles modified with phage-displayed peptides. Biomaterials 2011, 32:4943-4950.
29. Wang Z.H., Wang Z.Y., Sun C.S., Wang C.Y., Jiang T.Y., Wang S.L. Trimethylated chitosan-conjugated PLGA nanoparticles for the delivery of drugs to the brain. Biomaterials 2010, 31:908-915.
30. Preusser M., Capper D., Ilhan-Mutlu A., Berghoff A.S., Birner P., Bartsch R., et al. Brain metastases: pathobiology and emerging targeted therapies. Acta Neuropathol 2012, 123:205-222.
31. Nair M., Guduru R., Liang P., Hong J., Sagar V., Khizroev S. Externally controlled on-demand release of anti-HIV drug using magneto-electric nanoparticles as carriers. Nat Commun 2013, 4:1707.
32. Huang J.Y., Lu Y.M., Wang H., Liu J., Liao M.H., Hong L.J., et al. The effect of lipid nanoparticle PEGylation on neuroinflammatory response in mouse brain. Biomaterials 2013, 34:7960-7970.
33. Wang C., Cheng L., Liu Z. Drug delivery with upconversion nanoparticles for multi-functional targeted cancer cell imaging and therapy. Biomaterials 2011, 32:1110-1120.
34. Lu R.M., Chang Y.L., Chen M.S., Wu H.C. Single chain anti-c-Met antibody conjugated nanoparticles for invivo tumor-targeted imaging and drug delivery. Biomaterials 2011, 32:3265-3274.
35. Gao J.Q., Lv Q., Li L.M., Tang X.J., Li F.Z., Hu Y.L., et al. Glioma targeting and blood-brain barrier penetration by dual-targeting doxorubincin liposomes. Biomaterials 2013, 34:5628-5639.
36. Gan C.W., Feng S.S. Transferrin-conjugated nanoparticles of poly(lactide)-d-alpha-tocopheryl polyethylene glycol succinate diblock copolymer for targeted drug delivery across the blood-brain barrier. Biomaterials 2010, 31:7748-7757.